Vanderbilt-Ingram Cancer Center clinical trial pipeline

3 trials changed in the last 30 days: 1 stopped, 2 with notable changes, 0 with minor changes only.

1. Stopped

   Rigosertib Plus Pembrolizumab · Unresectable/Metastatic Melanoma…Rigosertib Plus Pembrolizumab · Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

   Trial terminated

   Sponsor's reason: Drug unavailable

   Also in this update: Results posted: Sep 16, 2026; Primary completion date changed from estimate of May 1, 2028 to Jul 15, 2025

   Vanderbilt-Ingram Cancer Center·Phase 2· NCT05764395· Registry history of NCT05764395 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

2. Notable

   Intrathecal Cytarabine and Hydrocortisone for the Early Treatment…Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma

   Primary endpoint(s) modified

   Also in this update: Recruitment opened; Primary completion moved earlier from Oct 1, 2029 to Mar 1, 2028

   Vanderbilt-Ingram Cancer Center·Phase 2· NCT07763210· Registry history of NCT07763210 on ClinicalTrials.gov (opens the registry)

   Updated Oct 2, 2026

3. Notable

   Casdatifan · Refractory Metastatic Clear Cell Renal Cell Carcinoma

   Phase changed: Early Phase 1 → Phase 1

   Also in this update: Recruitment opened

   Vanderbilt-Ingram Cancer Center·Phase 1· NCT07748988· Registry history of NCT07748988 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.